Stuart Arbuckle

Executive Vice President & Chief Operating Officer, Vertex Pharmaceuticals

Search every verified Stuart Arbuckle interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Stuart Arbuckle, Executive Vice President and Chief Operating Officer at Vertex Pharmaceuticals, discussed the company’s recent launch of Journavx (also referred to as genavix or Xonavic’s in the transcript) during the Q4 2024 earnings call. He described the drug’s approval as critical, stating that it represents the first new class of pain medicine in over 20 years, combining effective pain relief with a favorable safety profile and, based on its mechanism of action, no addiction potential. He noted its indication for all types of moderate to severe acute pain, including post-surgery, broken bones, and sports injuries, and expressed the view that it could establish a new standard of care for the 80 million patients seeking prescription therapy for such pain. Arbuckle also addressed pricing and market access for the drug, stating that Vertex priced Journavx at $15.50 per pill or $31 per day at list price. He said the company believes this price balances broad patient access with societal benefits, including potential cost offsets, while recognizing Vertex’s over 20-year investment in pain research. He mentioned ongoing discussions with payers and formulary committees to minimize utilization management controls and accelerate institutional reviews of the product, noting that some committees can take 12 to 18 months for new products but that the company is working to significantly shorten that timeline.